Get the Stockscreener App
3.78
1.61%
0.06
After Hours:
3.60
-0.18
-4.76%
Lixte Biotechnology Holdings Inc stock is traded at $3.78, with a volume of 240.34K.
It is up +1.61% in the last 24 hours and up +240.54% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$3.72
Open:
$3.85
24h Volume:
240.34K
Relative Volume:
0.12
Market Cap:
$10.15M
Revenue:
-
Net Income/Loss:
$-4.69M
P/E Ratio:
-1.6223
EPS:
-2.33
Net Cash Flow:
$-3.81M
1W Performance:
-10.43%
1M Performance:
+240.54%
6M Performance:
+62.58%
1Y Performance:
+60.85%
1-Day Range:
$3.45
$3.99
1-Week Range:
$2.75
$4.45
52-Week Range:
$0.64
$4.45
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
248 ROUTE 25A, EAST SETAUKET
Compare LIXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.78 | 8.32M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
Lixte Biotechnology Regains Nasdaq Compliance After Fundraising - TipRanks
LIXTE Biotechnology Regains Nasdaq Compliance with $5M Financing - AInvest
What makes Lixte Biotechnology Holdings Inc. Equity Warrant stock price move sharplyFree Consultation - beatles.ru
LIXTE Biotechnology's Compliance Win: A Turning Point for Clinical Gains and Stock Stability? - AInvest
LIXTE Biotechnology Holdings, Inc. Regains Nasdaq Compliance Following Successful Capital Raise - Quiver Quantitative
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements - GlobeNewswire
LIXTE Secures $6.5M Funding, Maintains Nasdaq Listing While Advancing Cancer Drug Trials - Stock Titan
How Lixte Biotechnology Holdings Inc. Equity Warrant stock performs during market volatility - Newser
What makes Lixte Biotechnology Holdings Inc. stock price move sharplyFree Stock Selection - Newser
How Lixte Biotechnology Holdings Inc. stock performs during market volatilityBreakout Level Watch - Newser
Why Lixte Biotechnology Holdings Inc. Equity Warrant stock attracts strong analyst attentionFree Access to Community - Newser
Why Lixte Biotechnology Holdings Inc. stock attracts strong analyst attentionTop Performer Shortlist - Newser
Lixte’s LB100 Clinical Trials Validated by Nature - TipRanks
LIXT 8-K: Nature Publication Validates Cancer Trial Mechanism | LIXTW SEC FilingForm 8-K - Stock Titan
Lixte Biotechnology Secures Strategic Capital to Accelerate Oncology Breakthroughs - AInvest
Lixte Biotechnology Closes $1.5M Direct Offering - The Globe and Mail
Spartan Capital Securities, LLC Serves as Placement Agent - GlobeNewswire
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct Offering - Yahoo Finance
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials - The Manila Times
New Clinical Findings Published in Scientific Journal - GlobeNewswire
Nature Journal Validates Cancer Breakthrough in Ovarian and Colorectal Treatment Study | LIXTW Stock News - Stock Titan
Lixte Biotechnology (NASDAQ:LIXT) Shares Up 12.9% – Still a Buy? - Defense World
Lixte Biotechnology raises $1.5 million in registered direct offering By Investing.com - Investing.com South Africa
Broadway Financial Corporation shares rise 1.98% after-hours following Spartan Capital Securities' $5.0 million private placement for Lixte Biotechnology Holdings, Inc. - AInvest
Lixte Biotechnology raises $1.5 million in registered direct offering - Investing.com Australia
Lixte Biotechnology: Balancing Financial Constraints with Oncology Innovation - AInvest
Lixte Biotechnology Closes $1.5 Million Registered Direct Offering - MarketScreener
Lixte Biotechnology announces $5M equity financing; shares down - MSN
LIXT raises $1.5 m via direct offering; issues shares & warrants | LIXTW SEC FilingForm 8-K - Stock Titan
Lixte Biotechnology Holdings, Inc. Closes $1.5 Million Registered Direct Offering of Common Stock - Nasdaq
Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering - GlobeNewswire
Clinical-Stage Pharma Lixte Biotech Just Raised $1.5M at $1.54 Per ShareKey Details Revealed - Stock Titan
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, ... - Bluefield Daily Telegraph
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $5.0 Million Private Placement - TradingView
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Did Lixte Biotechnology Plunge 13.78%? - AInvest
Biotech Stocks To Keep An Eye On – July 3rd - Defense World
Lixte Biotechnology Announces $5M Private Placement - The Globe and Mail
LIXT: Is a Growth Surge on the Horizon? - timothysykes.com
Lixte Biotechnology (NASDAQ:LIXTW) Stock Price Up 844.2% – What’s Next? - Defense World
Mogo Bets Big On Bitcoin, Inspira And Lixte Shine - Finimize
Lixte Biotechnology's $5M Private Placement: A Lifeline or a Liquidity Crisis? - AInvest
Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market - GlobeNewswire
Biotech Lixte Raises $5M to Advance Clinical Programs: Key Details of Strategic Financing - Stock Titan
Lixte Biotechnology Soars 12.71% on $5M Private Placement - AInvest
Lixte Biotechnology: Navigating Volatility Amid a $5M Financing Crossroads - AInvest
Lixte Biotechnology Holdings, Inc. Announces $5 Million Private Placement of Common Stock and Preferred Shares - Quiver Quantitative
Lixte Biotechnology secures $5 million in private placement By Investing.com - Investing.com UK
LIXTW SEC FilingsLixte Biotechnology Hldgs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lixte Biotechnology (NASDAQ:LIXT) Trading 20.5% Higher – What’s Next? - Defense World
Lixte Biotechnology Converts Preferred Stock to Common - TipRanks
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):